55 Results
Sort By:
Published on May 14, 2024
Scientists at the Johns Hopkins School of Medicine say they have uncovered insights as to why lupus symptoms and severity present differently in individuals. The researchers believe this discovery will lead to further understanding of the biological mechanisms behind lupus, and may lead to shifts in how clinicians treat patients.…
Published on April 17, 2024
As it expands from oncology into autoimmune disease, Cullinan Therapeutics (formerly Cullinan Oncology) yesterday announced a $280 million private placement. The company’s lead compound is now CLN-978 for systemic lupus erythematosus (SLE), which it believes has the potential to be a safe, first-in-class, off-the-shelf, disease-modifying treatment in autoimmune diseases. “Today’s…
Published on February 6, 2024
A new study, led by Australian researchers at Monash University, demonstrates a method to reprogram defective cells that could lead to a new cell therapy to provide an effective long-term treatment for lupus. Using human cells from healthy people, the research team developed a treatment that restores the protective aspects…
Published on March 10, 2023
Researchers at Linköping University in Sweden have discovered that C-reactive protein (CRP), a common biomarker that is routinely used to detect systemic inflammation, plays a beneficial role in systemic lupus erythematosus (SLE), the most common form of lupus. The research, published in the Journal of Autoimmunity, opens a new avenue…
Published on November 7, 2022
AMPEL BioSolutions has announced that its genetic precision medicine test for lupus patients could predict heart disease and provide decision support for prophylactic therapies. Shared genes that predispose both to lupus and cardiovascular disease are pinpointed in a report they published in Cell Reports Medicine. AMPEL’s approach characterizes inherited genetic markers that…
Published on June 19, 2019
Researchers part of a public-private partnership have identified new targets for the treatment of autoimmune diseases, including lupus and rheumatoid arthritis. That’s according to a trio of new studies published in the 18 June 2019 issue of Nature Immunologythat provide new details about how tissue damage occurs in these diseases.…
Published on May 22, 2019
Rare gene variants have been linked to systemic lupus erythematosus (SLE) by a group of scientists led by Carola G. Vinuesa, Ph.D., of the Australian National University. The research was published May 17 in Nature Communications. SLE is a highly heterogeneous autoimmune disease thought to be caused by the effects…
Published on May 9, 2024
Zenas BioPharma this week closed an upsized $200 million Series C financing. The company’s lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb to inhibit the activity of B cells, plasmablasts, and CD19-expressing plasma cells to treat autoimmune diseases. The financing round was…
Published on May 6, 2024
Female mammals are more susceptible to autoimmune diseases because of how their X-chromosome is inactivated, new research from France suggests. Scientists “turned back on” the inactive X gene in a mouse model, which led to signs of autoimmune disease. It’s likely the findings will relate to people as well. The…
Published on March 5, 2024
A large study led by Kyung Hee University in Seoul shows that infection with SARS-CoV-2 significantly increases the risk of developing autoimmune inflammatory rheumatic disease for up to a year after infection. The research, published in the Annals of Internal Medicine, shows that COVID-19 increased the risk for being diagnosed…
Published on February 28, 2024
A stunning response to CAR T therapy by patients with autoimmune disease was seen in a small study led by a group of German researchers. The use of CAR T in autoimmune diseases has been slowly ramping up over the last few years and this is one of the most…
Published on February 12, 2024
Already a popular topic, the launch of the large language model-based chatbot, ChatGPT, at the end of 2022 increased excitement around artificial intelligence (AI) in the media to fever pitch. This event triggered many heated debates about the technology and its numerous potential applications over the past 12 months. There…
Published on February 12, 2024
ol.custom-marker { counter-reset: list;}ol.custom-marker > li { list-style: none; counter-increment: list;}ol.custom-marker.parens-after.decimal > li::marker { content: counter(list) “)\a0”;} By Michael N. Liebman Biology embraces the existence of a central dogma, i.e., DNA → RNA → protein, and drug development has embraced its own, i.e., disease → target → drug, but both…
Published on February 2, 2024
A study has found clues as to why some autoimmune diseases may be more common in women than men, with the answer residing in their extra X chromosome. The findings suggest that the blame may specifically lie with a long non-coding RNA (lncRNA) that is normally only active in females,…
Published on December 27, 2023
AstraZeneca is acquiring cell therapy developer Gracell Biotechnologies Inc. for $1.2B. Gracell is focused on cancer and autoimmune diseases and, importantly, has a toehold in China. The biotech has ten programs in preclinical or later phases. Its most advanced candidate, GC012F, is in Phase I/II trials in the U.S. and…